BioSig Technologies Ranked Top 50 for The Silicon Review’s Innovative Companies to Watch in 2018
CEO, Ken Londoner featured for addressing market needs via unique solutions
Santa Monica, CA, July 24, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, was featured in The Silicon Review’s list of Top 50 Innovative Companies to Watch in 2018.
The Silicon Review garners more 160,000 unique visitors per month and appeals to business and technology professionals. Featuring CEOs from groundbreaking companies, such as Daniel Springer of DocuSign, this Top 50 Innovative Companies to Watch in 2018 list highlights individuals that are addressing market needs through providing unique solutions.
“We are extremely pleased and honored to have our Company and CEO, Mr. Ken Londoner, featured in this prominent publication highlighting the potential and innovation of the PURE EPTM System,” stated Mrs. Natasha Russkina, Vice President for Business Development & Corporate Finance of BioSig Technologies, Inc. “Recognition for the innovative work that the Company is conducting is reinforcing our belief that BioSig will continue to impact the disruptive bioelectronic medicine ecosystem.”
The Silicon Review’s dialog with Mr. Londoner displays his approach to developing a sustainable company with strategic financing and excellent leadership. With the electrophysiology market expected to reach $4.73 billion by 2019, the innovative PURE EPTM System will aim provide the solution to generating accurate clinical data through higher resolution and broader dynamic ranges.
To view the interview with Ken Londoner and The Silicon Review, click the link below.
The Silicon Review Interview With Ken Londoner
About BioSig Technologies
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP™ System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP™ System.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance firstname.lastname@example.org +41 (0) 76 823 7527
Released July 24, 2018